U.S. FDA approves AbbVie's JUVMO (tavapadon) for Parkinson's disease
The tablets are taken once daily, with or without levodopa therapy, the company said.
GetSignal AbbVie Inc. ABBV
AbbVie said on September 28, 2026, that the U.S. Food and Drug Administration approved JUVMO (tavapadon) tablets for the treatment of adults with Parkinson's disease, a progressive neurological disorder.
AbbVie said the approval is supported by the Phase 3 TEMPO program, which showed improvements in daily functioning, increased "on" time without troublesome dyskinesia and a favorable safety profile.
Key facts
- Drug
- JUVMO (tavapadon) tablets
- Indication
- Adults with Parkinson's disease
- Dosing
- Once daily, with or without levodopa therapy
- Approving agency
- U.S. Food and Drug Administration
Source: The company's release on PR Newswire, September 28, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
